The miRNA-mediated regulation of the TGF-β pathway and ECM synthesis positions SGLT2 inhibitors as promising therapeutic agents in the management of cardiovascular fibrosis associated with diabetes and heart failure. This evidence concerns the gene SLC5A2 and diabetes mellitus.